Sisram Medical Ltd is a global consumer wellness group specializing in energy-based medical aesthetic treatment systems and injectables. The company designs, develops, and produces devices for hair removal, skin rejuvenation, body contouring, and pigmentation treatment, alongside a portfolio of dermal fillers, neurotoxins, and biostimulators. Key brands include Alma, which provides energy-based solutions for surgical and medical aesthetics markets, and LMNT, a personal care brand for consumer wellness. The group also offers Copulla, a digital dentistry service for aesthetic treatments, and injectables such as Profhilo, Hallura, and DAXXIFY. Sisram Medical serves professional customers and consumers in North America and the Asia-Pacific region, including China, Thailand, and Japan. The company is part of the Fosun Pharma Med-Tech group and was established in 2013 following the acquisition of Alma. Its business model integrates devices, injectables, diagnostics, and skincare into a connected ecosystem, leveraging proprietary technologies and AI-enabled platforms like Alma IQ and Universkin by Alma to support personalized treatment planning and patient engagement.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Medical Devices Homepage sisram-medical.com
Sector Healthcare IR page sisram-medical.com/investor_relations
Tags
medical aesthetics, energy-based devices, injectables, dermal fillers, neurotoxins, biostimulators, skin rejuvenation, hair removal, body contouring, digital dentistry, personal care, ai diagnostics, Alma, LMNT, Copulla, Alma Harmony, Alma Hybrid, Profhilo, Hallura, DAXXIFY, Universkin by Alma, Alma IQ, Titanium Prime
Press page —

Metrics

Valuation  
Market cap HK$ 782.78M
Market cap (USD) $ 99.759M
P/E 5.29
PEG —
P/BV 0.20
P/S 0.27
P/OCF -36.41
P/FCF —
Dividend yield 5.7%
Turnover / mcap 0.04%
Returns  
ROE 3.8%
ROI 3.7%
ROIC 3.7%
Profit margin 5.2%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -22.1%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 7.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -5.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 365.347M 349.112M 359.292M 354.48M 294.294M 162.095M 173.52M 153.919M 136.887M 118.156M
Net profit 19.016M 25.126M 31.499M 40.17M 31.245M 13.344M 20.785M 21.831M 11.049M 8.055M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price — — — 1.03 1.04 — 0.51 — 0.81 —
P/E 5y avg — — — 12.65 15.59 — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Subject: Bull 3 Bear 0 Product/operations

Sisram Medical Accelerates DAXXIFY Commercialization in Mainland China Repeat-Purchase Clinics Contribute Over 60% of First-Year Sales, as Partner Network Expansion Exceeds Expectations HONG KONG, October 28, 2026 -- Sisram Medical Ltd (the “Company” or “Sisram”, 1696.HK), a global wellness group offering Energy-Based Devices (“EBD”), injectables, and other complementary solutions, today announced the latest commercial milestones for DAXXIFY, its first injectable product launched in Mainland China. Fueled by rising repeat uptake across partner clinics, DAXXIFY is advancing into the next stage of market adoption. The continued build-out of its premium clinic network and development of new channel partnerships further solidify the product’s commercial base and support its expansion trajectory in China. As at 30 September 2026, DAXXIFY was available at over 630 premium medical aesthetics clinics across Mainland China, exceeding prior disclosed coverage. Clinics placing repeat orders within the product’s launch year contributed more than 60% of total sales, representing an increase of nearly 20 percentage points from 42% as at 30 June 2026. This uptick points to a notable transition from initial trial adoption to regular reordering among core partners. Average sales per clinic have also trended upwards, signaling growing market recognition of DAXXIFY’s value proposition and competitive positioning within the premium medical aesthetics segment. In tandem with nurturing existing partner relationships, Sisram is rolling out DAXXIFY into new channels and customer cohorts. In September, the Company entered into a strategic partnership with JDH Medical Aesthetics to make DAXXIFY available via its digital platform and self-operated clinics. The parties will jointly implement an end-to-end product traceability system covering supply through to treatment administration. Under an integrated “online ordering, in-clinic delivery” model, the collaboration combines JDH Medical Aesthetics’ digital footprint and offline service network. This enables Sisram to access a wider consumer audience, while strengthening product authenticity safeguards, service standardization and brand exposure. To elevate professional support for partner clinics, Sisram has launched the PACE-4D Dynamic Facial Assessment System. The framework offers practitioners a standardized, structured facial evaluation methodology across four pillars: pattern, activity, continuity and epidermal quality. By embedding structured facial assessment into physician-patient consultations and personalized treatment planning, PACE-4D helps improve the precision and consistency of clinical outcomes and supports clinics in addressing individual patient requirements. For the next phase, Sisram will continue to deepen engagement with key medical aesthetics clinics, while refining injection protocols and medical support resources to stimulate end-consumer demand and repeat treatment uptake. Drawing on Alma’s established clinic footprint, the Company will further integrate its EBD and injectables businesses to extend DAXXIFY’s reach and capture cross-selling potential. Concurrently, Sisram will develop combination treatment protocols tailored for the Chinese market, delivering more holistic, customized aesthetic solutions.

1

“DAXXIFY has delivered encouraging results during its inaugural year in Mainland China, moving from the initial phase of clinic on-boarding to deeper penetration among benchmark clinics and a rising share of repeat-order revenue,” commented Mr. Jiahong Li, Co-CEO and CFO of Sisram. “This traction reflects growing validation of the product’s value, lays a robust commercial groundwork ahead of Profhilo’s upcoming launch in China, and reinforces our confidence in injectables as the Company’s second growth engine. Our priority going forward is to convert this momentum into improved commercialization efficiency and higher-quality growth. We will strengthen key account partnerships and broaden market coverage through multichannel online-offline distribution and Alma’s existing clinic network. We also plan to introduce additional innovative products into China and combine our EBD and injectables expertise to develop differentiated combination regimens adapted to local clinical practices and patient preferences. China remains a core strategic market for Sisram. By pairing our global innovation pipeline with robust local execution and close partner collaboration, we seek to capture further market opportunities and deliver sustainable long-term value for customers and shareholders.” About Sisram Medical Ltd Sisram Medical Ltd (1696.HK) is a global leader in medical aesthetic solutions with over 25 years of expertise in Energy-Based Devices (EBD). Built on a legacy of innovation and clinical excellence, the Company’s synergistic ecosystem spans EBD technologies, injectables, diagnostics, and complementary solutions. Serving customers in over 110 countries and regions, Sisram delivers award-winning products that set new standards in safety, efficacy, and personalized aesthetic care for millions of patients worldwide. Majority-owned by Fosun Pharma, Sisram has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017.

Prompts

Sisram Medical Ltd (ticker 1696), listed in Hong Kong.

ETFs Holding Sisram Medical Ltd

ETF Weight in ETF Shares Market value As of
AVDV 0.00% 19,200 $ 4,276.37 Nov 16, 2026